Abbott Laboratories (ABT) reported $44.3B in revenue for fiscal 2025, +5.7% year on year. That ranks #121 by revenue among 2853 SEC filers and #20 in Healthcare. Net income was $6.5B, a net margin of 14.7%. Revenue has grown 8.7% a year on average since 2016 ($20.9B then). The fiscal 2025 balance sheet shows $86.7B in total assets, $8.5B in cash and $9.9B in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $44.3B | +5.7% | FY20252025-12-31 |
| Gross profit | Not reported | — | |
| Operating incomeOperatingIncomeLoss | $8.1B | +18.0% | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $6.5B | −51.3% | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $9.6B | +11.8% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $2.2B | −1.6% | FY20252025-12-31 |
| Total assetsAssets | $86.7B | +6.5% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $52.1B | +9.4% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $8.5B | +11.9% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $9.9B | −21.6% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $11.2B | $1.1B | Open → |
| Q2 20262026-06-30 | $12.6B | $928M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Where this sits in its sector
Each bar is the spread of the whole sector: the box covers the middle half of companies, the line inside it the median, and the triangle this company. The axis is clipped at the 5th and 95th percentile so a single outlier does not flatten it.
| Where this sits in its sector | FY2025 | Position in sector |
|---|---|---|
| Net marginRank 39 of 161 companies compared | 14.7% | |
| Operating marginRank 42 of 160 companies compared | 18.2% | |
| R&D as share of revenueRank 59 of 102 companies compared | 6.6% | |
| Cash as share of revenueRank 56 of 160 companies compared | 19.2% |
All four are ratios derived from two reported lines, not single filing items. Peer group: companies in the same sector with revenue of $1bn or more; loss-making companies are included.
Profile
- Legal name
- Abbott Laboratories
- Ticker
- ABT
- Exchange
- NYSE
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0000001800
Filings
- 10-QJul 28, 2026Open filing →
- 10-QApr 29, 2026Open filing →
- 10-KFeb 20, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Bristol Myers SquibbBMY | $48.2B | $7.1B |
| Novo Nordisk A SNVO | $46.8B | $15.5B |
| Molina HealthcareMOH | $45.4B | $472M |
| Abbott LaboratoriesABT | $44.3B | $6.5B |
| GSKGSK | $43.1B | $7.5B |
| AmgenAMGN | $36.8B | $7.7B |
| MedtronicMDT | $36.4B | $4.8B |
Abbott Laboratories compared withMolina Healthcare
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Abbott Laboratories — Key figures |url=https://companiesranked.com/en/company/abbott-laboratories |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Abbott Laboratories — Key figures. CompaniesRanked. https://companiesranked.com/en/company/abbott-laboratoriesBibTeX
@misc{companiesranked-en-company-abbott-laboratories-2026,
author = {{CompaniesRanked}},
title = {{Abbott Laboratories — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/abbott-laboratories}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001628280-26-010185 · February 20, 2026
{{cite web |title=Abbott Laboratories — Key figures — 10-K (0001628280-26-010185) |url=https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/abt-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-20}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.